| Autor: |
Mehrdad Hashemi, Elaheh Mohandesi Khosroshahi, Saba Asadi, Mahsa Tanha, Forough Ghatei Mohseni, Ramina Abdolmohammad Sagha, Elham Taheri, Paria Vazayefi, Helya Shekarriz, Fatemeh Habibi, Shaghayegh Mortazi, Ramin Khorrami, Noushin Nabavi, Mohsen Rashidi, Afshin Taheriazam, Payman Rahimzadeh, Maliheh Entezari |
| Jazyk: |
angličtina |
| Rok vydání: |
2025 |
| Předmět: |
|
| Zdroj: |
Non-coding RNA Research, Vol 10, Iss , Pp 1-15 (2025) |
| Druh dokumentu: |
article |
| ISSN: |
2468-0540 |
| DOI: |
10.1016/j.ncrna.2024.08.002 |
| Popis: |
Cancer progression results from the dysregulation of molecular pathways, each with unique features that can either promote or inhibit tumor growth. The complexity of carcinogenesis makes it challenging for researchers to target all pathways in cancer therapy, emphasizing the importance of focusing on specific pathways for targeted treatment. One such pathway is the PI3K/Akt pathway, which is often overexpressed in cancer. As tumor cells progress, the expression of PI3K/Akt increases, further driving cancer advancement. This study aims to explore how ncRNAs regulate the expression of PI3K/Akt. NcRNAs are found in both the cytoplasm and nucleus, and their functions vary depending on their location. They can bind to the promoters of PI3K or Akt, either reducing or increasing their expression, thus influencing tumorigenesis. The ncRNA/PI3K/Akt axis plays a crucial role in determining cell proliferation, metastasis, epithelial-mesenchymal transition (EMT), and even chemoresistance and radioresistance in human cancers. Anti-tumor compounds can target ncRNAs to modulate the PI3K/Akt axis. Moreover, ncRNAs can regulate the PI3K/Akt pathway both directly and indirectly. |
| Databáze: |
Directory of Open Access Journals |
| Externí odkaz: |
|
